Sign in
Taking people in United StatesPhase 2

Acetazolamide for Obstructive Sleep Apnea: Effects on Sleep, Thinking and Quality of Life

Tests acetazolamide against placebo in adults with obstructive sleep apnea.

Key facts

Who runs it
University of California, San Diego
Where
La Jolla, United StatesSee the site
Trial code
Registry title
Patient-centered and Neurocognitive Outcomes With Acetazolamide for Sleep Apnea
Status
Recruiting
Phase
Phase 2
People taking part
60 people, planned
Started
16 May 2023
Planned end
31 Oct 2026
Type of study
Interventional, 2 groups
Treatments tested
  • Acetazolamide
  • Placebo
Record updated
8 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with untreated moderate or severe obstructive sleep apnea (breathing stops during sleep). It compares acetazolamide with a placebo (dummy pill), 4 weeks each.

Age
18 years and older
Sex
All sexes
Disease stage
Untreated moderate/severe obstructive sleep apnea (AHI ≥15/h, meaning 15 or more breathing pauses per hour). Body mass index ≤ 35 kg/m2.
Earlier treatment
No sleep apnea treatment during the past 1 month, and no plan to urgently start or restart it within 3 months.

Main reasons for not taking part

  • Very low blood oxygen during sleep (SpO2<80% for >10% of the home sleep test time, or >25% of sleep time in lab studies)
  • Urgent need for sleep apnea treatment, such as Epworth sleepiness score >18, commercial driver, or past sleep-related car accident
  • Serious uncontrolled heart, lung, hormone, kidney, liver, brain, mental health or urinary disorder (such as kidney stones)
  • Severe allergy to sulfa drugs, or taking another carbonic-anhydrase inhibitor (such as topiramate), thiazide/loop diuretic, opiates or sedatives
  • Current or planned pregnancy or breastfeeding

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Age ≥18 years
  • Body mass index ≤ 35 kg/m2
  • Untreated moderate/severe OSA (AHI ≥15/h)

Who cannot take part

  • Use of OSA therapy during the past 1 month, or plans to urgently resume/(re)start clinical OSA therapy within 3 months
  • Urgent need to initiate effective OSA therapy (i.e., Epworth sleepiness score >18, commercial driver, prior sleep-related car accident, or based on MD judgment)
  • Medications that may affect OSA or ventilatory control (e.g., opiates, sedatives)
  • Significant, uncontrolled cardiac, pulmonary, endocrine, renal, hepatic, neurocognitive, psychiatric, or urologic (e.g., kidney stones) disorder
  • Other major sleep disorder (e.g., narcolepsy)
  • Severe allergy to sulfa-drugs or taking another carbonic-anhydrase inhibitor (e.g., topiramate)
  • Substantial sleep hypoxemia (SpO2<80% for >10% of the monitoring time during the home sleep test, or for >25% of the total sleep time during any of the in-laboratory studies)
  • Abnormally low blood counts/electrolytes or renal function at baseline
  • Pregnancy/breastfeeding (current/planned)
  • Prisoners
  • Illicit substance abuse or >2 standard drinks of alcohol/day
  • Thiazide/loop diuretic (risk of hypokalemia)
  • Inability to give consent or follow procedures
  • Safety concern based on MD judgment

Where in United States

  • UC San Diego; Altman Clinical and Translational Research Institute BuildingLa Jolla, United StatesContact: Pamela DeYoung, RPSGTTaking people

About the trial

What the trial wants to find out

Obstructive sleep apnea (OSA) is a severe type of snoring causing people to choke in their sleep. It affects millions of Americans, causing many health problems. For example, patients with OSA often feel very sleepy and are at risk of falling asleep while driving. OSA also causes elevated blood pressure, memory problems and can severely affect quality of life. Patients with OSA are often treated with a face-mask that helps them breath at night but can be difficult to tolerate. In fact, about half the patients eventually stop using this mask. Because there are few other treatments (and no drug therapy), many OSA patients are still untreated.

Read full original descriptionShow less

Acetazolamide (a mild diuretic drug) has been used for over 50 years to treat many different conditions and is well tolerated. Recent data suggest, that acetazolamide may help OSA patients to not choke in their sleep and lower their blood pressure. Further, its low cost (66¢/day) and once-daily dosing may be attractive for OSA patients unable or unwilling to wear a mask each night. But previous studies had many limitations such as studying acetazolamide for only a few days and not capturing important outcomes. The goal of this study is to test if acetazolamide can improve sleep apnea, neurocognitive function and quality of life in adults with OSA, and to assess how it does that. Thus, the investigators will treat 60 OSA patients with acetazolamide or placebo for 4 weeks each. The order in which participants receive the drug or placebo will be randomized. At the end of each 4 week period the investigators will assess OSA severity, neurocognitive function and quality of life. Thus, this study will help assess acetazolamide's potential value for OSA treatment, and may also help to identify patients who are most likely to respond to acetazolamide.

Ultimately, this work promises a drug therapy option for millions of OSA patients who are unable to tolerate current treatments

The 2 groups in the trial

  • Acetazolamide, then PlaceboTreatment being tested

    Subjects will start with a 4-week ACETAZOLAMIDE regimen Day 1-27: Acetazolamide 500mg at bedtime at home Day 28: Acetazolamide 500mg at bedtime in the sleep laboratory After a wash-out period, subjects will then cross-over to a 4-week PLACEBO regimen: Day 1-27: Placebo (matching Acetazolamide 500mg) at bedtime at home Day 28: Placebo (matching Acetazolamide 500mg) at bedtime in the sleep laboratory

    Treatment: Acetazolamide and Placebo

  • Placebo, then AcetazolamideTreatment being tested

    Subjects will start with a 4-week PLACEBO regimen Day 1-27: Placebo (matching Acetazolamide 500mg) at bedtime at home Day 28: Placebo (matching Acetazolamide 500mg) at bedtime in the sleep laboratory After a wash-out period, subjects will then cross-over to a 4-week ACETAZOLAMIDE regimen: Day 1-27: Acetazolamide 500mg at bedtime at home Day 28: Acetazolamide 500mg at bedtime in the sleep laboratory

    Treatment: Acetazolamide and Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Patient-centered and Neurocognitive Outcomes With Acetazolamide for Sleep Apnea
Plain-language title
Acetazolamide for Obstructive Sleep Apnea: Effects on Sleep, Thinking and Quality of LifeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
8 May 2026